B. Riley Securities Maintains Buy on Longboard Pharmaceuticals, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has maintained its Buy rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and raised the price target from $36 to $45.
August 05, 2024 | 4:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B. Riley Securities has maintained its Buy rating on Longboard Pharmaceuticals and raised the price target from $36 to $45.
The Buy rating and increased price target from a reputable analyst firm like B. Riley Securities is likely to positively impact investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100